Ignite Creation Date:
2025-12-24 @ 1:13 PM
Ignite Modification Date:
2026-02-23 @ 10:36 PM
Study NCT ID:
NCT02559895
Status:
COMPLETED
Last Update Posted:
2020-05-14
First Post:
2015-09-22
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
Sponsor:
Alder Biopharmaceuticals, Inc.
Organization:
Study Overview
Official Title:
A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines
Status:
COMPLETED
Status Verified Date:
2020-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PROMISE 1
Brief Summary:
The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: